

FINANCIAL STATEMENTS (Unaudited)
For the period from 01.07.2025 to 31.12.2025




THE IBN SINA PHARMACEUTICAL INDUSTRY PLC


Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,
Dhaka-1207, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Unaudited)
As at 31 December 2025

		Amount in Taka	
	Notes	31 December 2025	30 June 2025
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	04.A	5,905,671,438	4,701,323,681
Capital Work-In-Progress	05.A	2,615,357,691	2,655,519,636
Right-of-Use Assets	05.B	3,220,029,873	1,932,358,746
Advances, Deposits & Prepayments	10.A.1	20,670,445	33,072,711
Financial Assets	06.A	8,911,000	33,715,070
		40,702,429	46,657,518
Current Assets :			
Financial Assets	7.B	3,091,429,502	2,845,250,397
Inventories	08.A	59,144,491	22,500,000
Trade and Other Receivables	09.A	1,883,708,381	1,808,087,123
Advances, Deposits & Prepayments	10.A.1	226,845,888	196,052,607
Cash & Cash Equivalents	11.A	586,486,178	503,707,520
		335,244,563	314,903,147
TOTAL ASSETS		8,997,100,940	7,546,574,078
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Equity attributable to the owners of the company:			
Share Capital	12	4,199,497,399	3,926,901,664
Tax Holiday Reserve	13	312,436,270	312,436,270
FVOCI Reserve	14	4,392,110	4,392,110
Retained Earnings	15.A	(20,903,911)	(15,544,331)
		3,903,572,930	3,625,617,615
Non Controlling Interests	15.B	105,263,184	70,946,596
LIABILITIES:			
Non-Current Liabilities:			
Long Term Finance	16.A	1,086,880,262	1,072,158,461
Employee Benefit Obligations	17.A	984,777,983	974,705,376
Deferred Tax Liabilities	19	1,629,086	990,546
		100,473,193	96,462,538
Current Liabilities:			
Short Term Finance	20.A	3,605,460,095	2,476,567,357
Current Portion of Long Term Finance	21	1,797,387,709	953,683,239
Lease Liabilities	17.B	59,746,323	119,445,855
Trade and Other Payable	22.A	9,820,926	23,798,698
Unclaimed Dividend	22.B	1,028,636,994	842,289,127
Provision for Corporate Tax	23.A	72,718,559	42,104,508
		637,149,585	495,245,930
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		8,997,100,940	7,546,574,078
Net Assets Value (NAV) Per Share	31.A	134.41	125.69


Chief Financial Officer


Company Secretary



Director


Dated, Dhaka .
26 January 2026
Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)
For the Half-Year ended 31 December 2025

Notes	Amount in Taka			
	For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)	For the Quarter (1 October 2025 to 31 December 2025)	For the Quarter (1 October 2024 to 31 December 2024)
REVENUE				
Cost of goods sold	24.A 24.C	7,465,169,752 (4,413,910,280)	5,930,046,291 (3,534,028,829)	3,748,496,603 (2,237,438,694)
GROSS PROFIT		3,051,259,472	2,396,017,462	1,511,057,909
OPERATING EXPENSES		(2,363,438,517)	(1,930,906,619)	(1,169,518,229)
Administrative expenses	25.A	(135,374,187)	(134,115,019)	(65,477,293)
Selling and Distribution expenses	26.A	(2,228,064,330)	(1,796,791,600)	(1,104,040,936)
OPERATING PROFIT		687,820,955	465,110,843	341,539,680
Finance charges	34	(51,452,579)	(38,753,623)	(24,745,892)
Other income		18,311,423	11,728,648	8,863,211
Profit before WPPF and welfare fund		654,679,799	438,085,868	325,656,999
Workers' P.P. fund and welfare fund	27.A	(32,129,881)	(25,290,807)	(16,030,186)
PROFIT BEFORE TAX		622,549,918	412,795,062	309,626,813
Income tax expenses	28.A	(145,318,801)	(116,927,876)	(53,321,464)
PROFIT FOR THE PERIOD		477,231,117	295,867,185	256,305,349
PROFIT /(LOSS) ATTRIBUTABLE TO:				
Owners of the Company		477,914,529	295,407,951	256,688,000
Non-controlling interest		(683,412)	459,234	(984,172)
		477,231,117	295,867,185	255,703,828
Other Comprehensive Income:				
Change in fair value of Marketable Securities	29	(5,955,089)	(3,056,462)	(9,259,763)
Less: Deferred tax		595,509	305,646	925,976
Total other comprehensive income for the period, net of tax		(5,359,580)	(2,750,816)	(8,333,787)
Total Comprehensive Income for the period		471,871,537	293,116,370	247,971,562
Total Comprehensive Income Attributable to:				
Owner of the Company		472,554,949	292,657,136	248,354,213
Non-controlling interest		(683,412)	459,234	(984,172)
		471,871,537	293,116,370	247,370,041
Earnings Per Share (EPS)	30.A	15.27	9.47	8.20
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627


Chief Financial Officer

Company Secretary

Director

Dated, Dhaka .
26 January 2026

Managing Director

Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the Half-Year ended 31 December 2025


Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Amount in Taka
Balance as at 1 July 2024	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,718	3,533,360,493
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2025			(6,933,611)	633,189,350	66,877	626,322,617
Dividend for the year 30 June 2024 (Cash-63%) Issued during the year				(196,834,850)		(196,834,850)
					35,000,000	35,000,000
Balance as at 30 June 2025	312,436,270	4,392,110	(15,544,332)	3,625,617,614	70,946,595	3,997,848,260
Statement of profit or loss and other Comprehensive Income for period ended 31 December, 2025			(5,359,580)	477,914,529	(683,412)	471,871,536
Dividend for the year 30 June, 2025 (Cash-64%) Issued during the period				(199,959,213)		(199,959,213)
					35,000,000	35,000,000
Balance as at 31 December 2025	312,436,270	4,392,110	(20,903,912)	3,903,572,930	105,263,183	4,304,760,583


STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the Half-Year ended 31 December 2024

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Amount in Taka
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,706,202,754	35,051,367	3,055,816,151
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	670,522,122	828,351	665,006,105
Dividend for the year 30 June 2023 (Cash-60%)				(187,461,762)		(187,461,762)
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,719	3,533,360,493
Statement of profit or loss and other Comprehensive Income for period ended 31 December, 2024			(2,750,816)	295,407,951	459,234	293,116,369
Dividend for the year 30 June, 2024 (Cash-63%)				(196,834,850)		(196,834,850)
Balance as at 31 December 2024	312,436,270	4,392,110	(11,361,537)	3,287,836,215	36,338,953	3,629,642,013



Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)
For the Half-Year ended 31 December 2025

	Amount in Taka	
	Half-year ended 31.12.2025	Half-year ended 31.12.2024
Cash Flows From Operating Activities:		
Received from revenue and others	7,434,376,470	5,933,704,334
Payment for operation, expenses & others	(6,537,838,174)	(5,280,487,091)
Miscellaneous income	393,827	903,243
Cash generated from operations	896,932,123	654,120,486
Income tax paid	(78,552,144)	(78,685,686)
Payment for Financial charges	(50,506,436)	(36,620,120)
Net cash provided by operating activities	767,873,543	538,814,680
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(1,367,008,049)	(387,287,968)
Acquisition of financial assets	(30,689,402)	90,643,806
Received from bank	1,933,524	3,643,126
Net cash used in investing activities	(1,395,763,927)	(293,001,036)
Cash Flows From Financing Activities:		
Payment of dividend	(169,345,162)	(157,920,405)
Payment of lease liabilities	(14,923,915)	(14,486,825)
Long term finance received/(paid) from bank (Net)	10,072,607	178,424,544
Transactions Non Controlling Interests	35,000,000	-
Short term finance received/(paid) from bank (Net)	784,004,937	(336,367,661)
Net cash provided by financing activities	644,808,467	(330,350,348)
Increase/(decrease) in cash and cash equivalents	16,918,084	(84,536,704)
Cash and cash equivalents at 1 July	314,903,147	365,229,893
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	3,423,332	(46,902)
Cash and cash equivalents at 31 December	335,244,563	280,646,287
NOCFPS (Note 32.A)	24.58	17.25



Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director



Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF FINANCIAL POSITION (Unaudited)

As at 31 December 2025

	Notes	Amount in Taka	
		31 December 2025	30 June 2025
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	04	5,881,757,434	4,710,090,479
Capital Work-In-Progress	05	2,366,630,147	2,431,653,536
Right-of-Use Assets	05.B	2,330,923,943	1,155,822,174
Financial Assets	06	20,670,445	33,072,711
Advances, Deposits & Prepayments	10.1	11,702,429	17,657,518
Investment in Subsidiaries	07	8,661,000	33,715,070
		1,143,169,470	1,038,169,470
Current Assets :		2,662,526,609	2,424,153,681
Financial Assets	07.A	59,144,491	22,500,000
Inventories	08	1,666,894,004	1,603,775,310
Trade and Other Receivables	09	215,741,026	187,596,187
Advances, Deposits & Prepayments	10.1	530,686,715	429,600,396
Cash & Cash Equivalents	11	190,060,372	180,681,788
TOTAL ASSETS		8,544,284,043	7,134,244,160
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:			
Share Capital	12	4,195,293,329	3,932,383,056
Tax Holiday Reserve	13	312,436,270	312,436,270
FVOCI Reserve	14	4,392,110	4,392,110
Retained Earnings	15	(20,903,911)	(15,544,331)
		3,899,368,860	3,631,099,007
LIABILITIES:			
Non-Current Liabilities:		866,233,075	848,925,369
Long Term Finance	16	765,988,631	753,223,072
Employee Benefit Obligations	17	1,629,086	990,546
Deferred Tax Liabilities	18	98,615,358	94,711,750
Current Liabilities:		3,482,757,640	2,352,935,735
Short Term Finance	20	1,776,539,472	933,771,898
Current Portion of Long Term Finance	21	59,746,323	119,445,855
Lease Liabilities	17.B	9,820,926	23,798,698
Trade and Other Payables	22	975,645,837	775,229,847
Unclaimed Dividend	22.B	72,718,559	42,104,508
Provision for Corporate Tax	23	588,286,523	458,584,929
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		8,544,284,043	7,134,244,160
Net Assets Value (NAV) Per Share	31	134.27	125.86


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director



Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY PLC


STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)

For the Half-Year ended 31 December 2025

Notes	Amount in Taka			
	For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)	For the Quarter (1 October 2025 to 31 December 2025)	For the Quarter (1 October 2024 to 31 December 2024)
REVENUE	24	6,656,319,403	5,409,918,654	3,342,272,340
Cost of goods sold	24.B	(3,961,391,054)	(3,223,746,603)	(2,010,436,948)
GROSS PROFIT		2,694,928,349	2,186,172,051	1,331,835,392
OPERATING EXPENSES		(2,030,209,497)	(1,651,927,422)	(1,000,249,895)
Administrative expenses	25	(102,360,646)	(112,648,751)	(47,403,485)
Selling & Distribution expenses	26	(1,927,848,851)	(1,539,278,671)	(952,846,410)
OPERATING PROFIT		664,718,853	534,244,629	331,585,498
Finance charges	34	(51,452,579)	(38,753,623)	(24,745,892)
Other income		18,034,423	8,366,101	8,586,211
Profit before WPPF and welfare fund		631,300,696	503,857,107	315,425,816
Workers' P.P. fund and welfare fund	27	(30,061,938)	(23,993,196)	(15,020,277)
PROFIT BEFORE TAX		601,238,759	479,863,911	300,405,540
Income tax expenses	28	(133,009,692)	(112,936,413)	(47,549,184)
PROFIT FOR THE PERIOD		468,229,066	366,927,499	252,856,355
Other Comprehensive Income:				
Change in fair value of Marketable Securities	29	(5,955,089)	(3,056,462)	(9,259,763)
Less: Deferred tax		595,509	305,646	925,976
Total other comprehensive income for the period, net of tax		(5,359,580)	(2,750,816)	(8,333,787)
Total Comprehensive Income for the period		462,869,486	364,176,683	244,522,568
Earnings Per Share (EPS)	30	14.99	11.74	7.83
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director



Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the Half-Year ended 31 December 2025


Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Amount in Taka
Balance as at 1 July 2024	312,436,270	4,392,110	(8,610,721)	3,167,771,833	3,475,989,493
Statement of profit or loss and other Comprehensive Income-2024-25			(6,933,611)	660,162,024	653,228,413
Dividend for the year 30 June, 2024 (Cash-63%)				(196,834,850)	(196,834,850)
Balance as at 30 June 2025	312,436,270	4,392,110	(15,544,332)	3,631,099,007	3,932,383,056
Statement of profit or loss and other Comprehensive Income for period ended 31 December 2025			(5,359,580)	468,229,066	462,869,486
Dividend for the year 30 June, 2025 (Cash-64%)				(199,959,213)	(199,959,213)
Balance as at 31 December 2025	312,436,270	4,392,110	(20,903,912)	3,899,368,860	4,195,293,329


STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the Half-Year ended 31 December 2024


Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Amount in Taka
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,700,165,629	3,014,727,658
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	655,067,965	648,723,597
Dividend for the period 30 June 2023 (Cash -60%)				(187,461,762)	(187,461,762)
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,721)	3,167,771,833	3,475,989,493
Statement of profit or loss and other Comprehensive Income for period ended 31 December 2024			(2,750,816)	366,927,499	364,176,683
Dividend for the year 30 June 2024 (Cash-63%)				(196,834,850)	(196,834,850)
Balance as at 31 December 2024	312,436,270	4,392,110	(11,361,537)	3,337,864,481	3,643,331,325


Chief Financial Officer


Company Secretary


Director



Dated, Dhaka .
26 January 2026


Managing Director



Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
 STATEMENT OF CASH FLOWS (Unaudited)
 For the Half-Year ended 31 December 2025

	Amount in Taka	
	Half-year ended 31.12.2025	Half-year ended 31.12.2024
Cash Flows From Operating Activities:		
Received from revenue and others	6,628,174,563	5,402,228,789
Payment for operation, expenses & others	(5,753,766,978)	(4,782,358,826)
Miscellaneous income	393,827	903,243
Cash generated from operations	874,801,412	620,773,206
Income tax paid	(74,449,586)	(76,940,255)
Payment for Financial charges	(50,506,436)	(36,620,120)
Net cash provided by operating activities	749,845,390	507,212,831
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(1,221,421,783)	(290,501,594)
Investment in Subsidiary	(105,000,000)	(50,000,000)
Acquisition of financial assets	(30,689,402)	69,865,491
Received from bank	1,656,524	
Net cash used in investing activities	(1,355,454,661)	(270,636,103)
Cash Flows From Financing Activities:		
Payment of dividend	(169,345,162)	(157,920,405)
Payment of lease liabilities	(14,923,915)	(14,306,825)
Long term finance received/(paid) from bank (Net)	12,765,558	88,590,529
Short term finance received/(paid) from bank (Net)	783,068,041	(244,359,331)
Net cash provided by financing activities	611,564,522	(327,996,033)
Increase/(decrease) in cash and cash equivalents	5,955,252	(91,419,305)
Cash and cash equivalents at 1 July	180,681,788	312,475,845
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	3,423,332	(46,902)
Cash and cash equivalents at 31 December	190,060,372	221,009,638
NOCFPS (Note 32)	24.00	16.23


 Chief Financial Officer


 Company Secretary


 Director

Dated, Dhaka.
 26 January 2026


 Managing Director


 Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
SELECTED NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED)
For the Half-Year ended 31 December 2025

SELECTED EXPLANATORY NOTES:

1.1 The company and the group

The IBN SINA Pharmaceutical Industry PLC (the "Company") was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd., 99.99% The IBN SINA Natural Medicine Ltd. and 65% The IBN SINA Polymer Industry Ltd.; The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

1.2 Nature of business

The Company involves in production of pharmaceutical drugs and natural medicines and selling them in both local and international market.

2 Basis of preparation

2.1 Statement of compliance

These interim financial statements have been prepared in accordance with the International Accounting Standard IAS 34: Interim Financial Reporting, the Companies Act 1994, the Securities and Exchange Rules 2020, Financial Reporting Act 2015, relevant guidelines issued by Bangladesh Securities and Exchange Commission ("BSEC") and other applicable laws and regulations in Bangladesh.

The financial statements have been prepared on a historical cost basis, except for financial assets that have been measured at fair value where applicable. The financial statements provide comparative information in respect of the previous period and have been prepared on going concern basis. The interim financial statements should be read in conjunction with The IBN SINA Pharmaceutical Industry PLC's annual statutory financial statements as at 30 June 2025.

2.2 Date of authorisation

The interim financial statements were authorised for issue by the Board of Directors on 26 January 2026 for publication.

2.3 Functional and presentation currency

The financial statements are presented in Bangladeshi Taka (BDT), which is both functional and presentation currency of The IBN SINA Pharmaceutical Industry PLC.

2.4 Significant accounting policies

The same accounting policies and methods of computation have been followed in these interim financial statements as were applied in the preparation of the audited financial statements of The IBN SINA Pharmaceutical Industry PLC as at and for the year ended 30 June 2025.

3 Significant Deviations

3.1 EARNINGS PER SHARE (EPS):

Earnings per share has been calculated based on number of shares outstanding for the period ended 31 December 2025 and profit for the same period. The number of shares outstanding for the period was 31,243,627. Earnings per share for the corresponding period of 2024 has also been calculated based on 31,243,627 shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

3.2 SUBSEQUENT EVENTS:

No material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

3.3 INCREASE IN EARNINGS PER SHARE (EPS):

As a result of increase in Sales , EPS has been increased during current period over last reporting period.

3.4 INCREASE IN NET OPERATING CASH FLOW PER SHARE (NOCFPS):

Net operating cash flow per share (NOCFPS) increased during current period over last reporting period due to decrease in payment for cost & expenses & others.

3.5 INCOME TAX:

Payment of income tax decreased due to decrease in tax rate and net profit. advance income tax also increased due to payment for quarterly installment.

3.6 PAYMENT FOR FIXED ASSETS:

Payment for purchases of fixed assets increased due to increase in addition of fixed assets during this reporting period.

3.7 Other income increased during the period due to increase in revenue from toll production charge.

3.8 Payment of dividend increased due to declaration of higher dividend on last year's income during the reporting period.

3.9 FINANCE CHARGE:

Finance charge during the reporting period increased due to increase of long term loan.

3.10 INCREASE IN REVENUE:

The main objective of the company is to increase revenue which is essential for survival in the market. Due to increase in demand for the company's product in market, revenue has been increased during current period over last reporting period.

3.11 CASH FLOWS FROM INVESTING ACTIVITIES:

Cash flows from investing activities increased during the reporting period due to increased payment made for purchase of fixed assets and payment of share capital of The IBN SINA API Industry Ltd. And The IBN SINA Polymer Industry Ltd. than the same period of last year.

3.12 SHORT TERM FINANCE:

Short term finance increased during the period due to increase in import of raw materials under sight LC arrangement.

3.13 Previous period figures have been re-arranged to conform to current period presentation, where considered necessary.

31 December 2025	30 June 2025
------------------	--------------

04. PROPERTY, PLANT AND EQUIPMENT:

Cost :		
Opening balance	4,169,069,419	3,956,915,644
Addition during the period	22,724,976	215,232,652
Disposal/Adjustment during the period	(3,078,877)	
Closing balance	4,191,794,395	4,169,069,419
Accumulated Depreciation:		
Opening balance	1,737,415,882	1,554,782,910
Charged during the period	87,748,365	185,554,095
Disposal/Adjustment during the period	(2,921,123)	
Closing balance	1,825,164,247	1,737,415,883
Closing balance of written Down Value (WDV)	2,366,630,147	2,431,653,536

The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company.

04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:

The IBN SINA Pharmaceutical Industry PLC	2,366,630,147	2,431,653,536
The IBN SINA API Industry Ltd.	167,949,699	142,245,156
The IBN SINA Natural Medicine Ltd.	78,259,172	79,332,838
The IBN SINA Polymer Industry Ltd.	2,518,673	2,288,106
	2,615,357,691	2,655,519,636

05. CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)		
Opening balance	711,323,283	366,379,612
Addition during the period	100,659,855	344,943,671
Less: Transferred to property plant and equipment		
Closing balance	811,983,138	711,323,283
B) Machinery in transit and installation		
Opening balance	398,469,652	213,664,954
Addition during the period	1,098,036,952	310,149,835
Less: Transferred to property, plant and equipment	(125,345,137)	
	1,496,506,604	398,469,652
C) Other Goods-In-Transit	22,434,201	46,029,239
	2,330,923,943	1,155,822,174

i) Some new construction is under process to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC. The amount in machinery in transit represents the amount for opening the LC for the procurement of Factory machineries for newly constructed factory building and increasing production capacity of existing factory which are not received yet by the company.

05.A CONSOLIDATED CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)		
Opening balance	939,492,119	465,469,776
Addition during the period	182,921,796	474,022,343
Less: Transferred to property plant and equipment		
Closing balance	1,122,413,915	939,492,119
B) Machinery in transit and installation		
Opening balance	946,837,388	673,427,435
Addition during the period	1,128,344,369	398,755,090
Less: Transferred to property, plant and equipment	(125,345,137)	
Closing balance	2,075,181,757	946,837,388
Other Goods-In-Transit	22,434,201	46,029,239
	3,220,029,873	1,932,358,746

	Amount in Taka	
	31 December 2025	30 June 2025
05.B RIGHT-OF-USE ASSETS:		
Opening balance	130,252,602	130,252,602
Addition during the period	-	-
Disposal/Adjustment during the period	-	-
Closing balance	130,252,602	130,252,602
Accumulated Depreciation:		
Opening balance	97,179,890	72,375,357
Addition during the period	12,402,267	24,804,533
Disposal/Adjustment during the period	-	-
Closing balance	109,582,157	97,179,890
Closing balance of Written Down Value (WDV)	20,670,445	33,072,711
06. FINANCIAL ASSESTS (NON-CURRENT PORTION):		
Exim Bank PLC	1,140,000	2,090,000
First Security Islami Bank PLC	3,896,900	7,793,800
Shahjalal Islami Bank PLC	1,699,500	1,699,500
Al-Arafah Islami Bank PLC	1,622,250	1,849,365
Social Islami Bank PLC	520,929	1,284,958
Islami Bank Bangladesh PLC (IBBL) in MPB	2,822,850	2,939,895
	11,702,429	17,657,518
The above investment in marketable securities are designated as Fair Value through Other Comprehensive Income (FVOCI) by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income. The shares of Exim Bank PLC and IBBL-MPB are listed in Dhaka Stock Exchange PLC and Chittagong Stock Exchange PLC. The whole investment in shares of both the companies are in DSE only.		
06.A CONSOLIDATED FINANCIAL ASSESTS (NON-CURRENT PORTION):		
Exim Bank PLC	1,140,000	2,090,000
First Security Islami Bank PLC	3,896,900	7,793,800
Shahjalal Islami Bank PLC	1,699,500	1,699,500
Al-Arafah Islami Bank PLC	1,622,250	1,849,365
Social Islami Bank PLC	520,929	1,284,958
Islami Bank Bangladesh PLC (IBBL) in MPB	2,822,850	2,939,895
Investment in API Industrial Park Services Ltd.	29,000,000	29,000,000
	40,702,429	46,657,518
07 INVESTMENT IN SUBSIDIARIES :		
The IBN SINA API Industry Ltd.	709,999,800	669,999,800
The IBN SINA Natural Medicine Ltd.	238,169,670	238,169,670
The IBN SINA Polymer Industry Ltd.	195,000,000	130,000,000
	1,143,169,470	1,038,169,470
i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company. Tk.4 crore have been paid as a part of share capital.		
ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.		
iii) The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company. Tk. 6.5 crore have been paid as a part of share capital.		
07.A FINANCIAL ASSESTS (CURRENT PORTION):		
Opening balance (Investment in MTD)	22,500,000	89,500,000
During the period/year	36,644,491	-
MTDR-Closed during the period	-	(67,000,000)
Investment in Mudaraba Term Deposit	59,144,491	22,500,000
MTDR amount in Tk.36,644,491 is restricted for LC security purpose.		
07.B CONSOLIDATED FINANCIAL ASSESTS (CURRENT PORTION):		
Opening Balance	22,500,000	22,500,000
During the period/year	36,644,491	-
Investment in Mudaraba Term Deposit	59,144,491	22,500,000

	Amount in Taka	
	31 December 2025	30 June 2025
08. INVENTORIES:		
Raw materials	677,068,657	661,133,854
Packing materials	245,972,884	230,992,875
Work-in-process	118,133,623	97,983,312
Finished goods	367,714,938	357,701,249
Physicians' samples	5,960,322	5,836,177
Pad & literature	4,290,300	4,127,335
Spares & stores	387,044	360,234
Indirect materials	468,148	463,694
Printing & stationery	406,128	393,698
Laboratory chemicals	237,779	236,318
Material in transit	246,254,181	244,546,564
	1,666,894,004	1,603,775,310

i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces , some are in box and some are in kg, gram, milli gram, ton, liter and pcs as such quantity can not be inserted.
 ii) There is no damage goods or slow moving item in the inventory list.
 iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.
 iv) Inventory for raw materials , packing materials, Work In Process, Finished goods and material in transit increased during the period for ensuring smooth supply of goods to meetup increased customer demand.

08.A CONSOLIDATED INVENTORIES:

Raw materials	761,297,623	768,094,729
Packing materials	279,990,940	245,848,438
Work-in-process	130,897,989	111,124,876
Finished goods	450,647,310	424,409,351
Physicians' samples	8,830,939	8,481,886
Pad & literature	4,290,300	4,127,335
Spares & stores	387,044	360,234
Indirect materials	468,148	463,694
Printing & stationery	406,128	393,698
Laboratory chemicals	237,779	236,318
Material in transit	246,254,181	244,546,564
	1,883,708,381	1,808,087,123

09. TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	209,382,707	181,402,168
Receivable from provident fund (PF)	304,966	304,966
Profit receivable from MTD	1,666,635	3,391,971
Other receivable-toll charge	4,386,718	2,497,081
	215,741,026	187,596,187

i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due by the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.
 ii) Other receivable increased during the period due to increased toll charge.
 iii) Trade receivable increased during the period due to increase in sales revenue and customer types.

09.A CONSOLIDATED TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	220,487,569	189,858,588
Receivable from provident fund (PF)	304,966.00	304,966
Profit receivable from MTD	1,666,635	3,391,971
Other receivable-toll charge	4,386,718	2,497,081
	226,845,888	196,052,607

	Amount in Taka	
	31 December 2025	30 June 2025
10. ADVANCES, DEPOSITS AND PREPAYMENTS :		
a. Advances against		
Salary	7,001,705	5,482,341
Expenses/works/others	12,380,214	12,433,414
Depot rent	6,858,981	6,727,985
Motor cycles-to employees	42,563,988	42,143,838
Others	697,768	706,533
	<u>69,502,656</u>	<u>67,494,111</u>
b. Income tax		
Opening balance	374,539,128	200,028,807
Addition	74,449,586	174,510,320
Adjusted during the period	<u>448,988,713</u>	<u>374,539,128</u>
c. Deposits		
Security money	<u>20,856,322</u>	<u>21,275,544</u>
d. Pre payments		
Value Added Tax	23	6,683
	<u>539,347,715</u>	<u>463,315,466</u>
10.1 MATURITY ANALYSIS:		
Realizable/adjustable within one year.	530,686,715	429,600,396
Realizable/adjustable after one year.	<u>8,661,000</u>	<u>33,715,070</u>
	<u>539,347,715</u>	<u>463,315,466</u>
10.A CONSOLIDATED ADVANCES, DEPOSITS AND PREPAYMENTS :		
a. Advances against		
Salary	11,471,975	9,555,942
Expenses/works/others	13,339,998	31,119,648
Depot rent	6,858,981	6,727,985
Motor cycles-to employees	56,524,029	61,431,738
Others	2,590,291	2,101,636
	<u>90,785,274</u>	<u>110,936,949</u>
b. Income tax		
Opening balance	404,148,716	223,481,751
Addition	78,552,144	180,666,965
Adjusted during the period	<u>482,700,860</u>	<u>404,148,716</u>
c. Deposits		
Security money	21,911,019	22,330,241
d. Pre payments		
Value Added Tax	23	6,683
	<u>595,397,177</u>	<u>537,422,590</u>

The company did not give any advance, deposit and prepayment to the director's of the company, subsidiaries and other connected parties and employees advances are realised in normal course of business.

10.A.1 MATURITY ANALYSIS:

Realizable/adjustable within one year.	586,486,178	503,707,520
Realizable/adjustable after one year.	8,911,000	33,715,070
	<u>595,397,178</u>	<u>537,422,590</u>

11. CASH AND CASH EQUIVALENTS:

a. Cash in hand	8,137,054	6,613,494
b. Cash at bank	178,383,318	170,528,294
c. Imprest cash	3,540,000	3,540,000
	<u>190,060,372</u>	<u>180,681,788</u>

	Amount in Taka		
	31 December 2025	30 June 2025	
11.A CONSOLIDATED CASH AND CASH EQUIVALENTS:			
a. Cash in hand	9,479,502	7,137,453	
b. Cash at bank	322,095,061	304,095,694	
c. Imprest cash	3,670,000	3,670,000	
	<u><u>335,244,563</u></u>	<u><u>314,903,147</u></u>	
12. SHARE CAPITAL:			
Authorized:			
50,000,000 Ordinary Shares of Tk. 10 each	<u><u>500,000,000</u></u>	<u><u>500,000,000</u></u>	
Issued, Subscribed & Paid-Up :			
31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash	<u><u>312,436,270</u></u>	<u><u>312,436,270</u></u>	
The Shareholdings consist of :			
Holders	No. of Holders	Total Holdings	Percentage
Sponsors	1	13,843,312	44.31%
Institution (I.C.B)	207	7,624,427	24.40%
General Public	12,157	9,775,888	31.29%
	12,365	31,243,627	100.00%
The distribution schedule showing the number of share holders and their share holdings as on 30.12.2024 are as follows:			
Range of Holdings	No. of Holders	Total Holdings	Percentage
Less than 500 shares	9,750	1,736,642	5.97%
500 to 5,000 shares	2,234	3,333,683	11.36%
5,001 to 10,000 shares	194	1,411,886	4.69%
10,001 to 20,000 shares	90	1,211,208	4.73%
20,001 to 30,000 shares	28	655,673	2.98%
30,001 to 40,000 shares	10	355,707	2.00%
40,001 to 50,000 shares	14	642,700	1.83%
Above 50,000 shares	45	21,896,128	66.43%
	12,365	31,243,627	100.00%
The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange PLC The shares were quoted at Tk.314 in the Dhaka Stock Exchange PLC on 30.12.2025 and at Tk.315.00 in the Chittagong Stock Exchange Limited on 30.12.2025 respectively.			
13. TAX HOLIDAY RESERVE:	<u><u>4,392,110</u></u>	<u><u>4,392,110</u></u>	
This represents provision made out of profit of Tax Holiday period in accordance with section 45 (2B) and section 46A (2) of Income Tax Ordinance 1984.			
14. FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVOCI) RESERVE:			
Closing market value of marketable securities	11,702,429	17,657,518	
Less: Cost of marketable securities	34,928,997	34,928,997	
Unrealized gain before adjustment of deferred tax	<u><u>(23,226,568)</u></u>	<u><u>(17,271,479)</u></u>	
Less: Deferred tax on unrealized gain/(loss)	2,322,657	1,727,148	
Net unrealized gain/(loss) on marketable securities	<u><u>(20,903,911)</u></u>	<u><u>(15,544,331)</u></u>	
15. RETAINED EARNINGS:			
Opening Balance	3,631,099,007	3,167,771,833	
Dividend paid	(199,959,213)	(196,834,850)	
Add : Net profit during the period	468,229,066	660,162,024	
	<u><u>3,899,368,860</u></u>	<u><u>3,631,099,007</u></u>	
15A. CONSOLIDATED RETAINED EARNINGS:			
Opening Balance	3,625,617,615	3,189,263,114	
Dividend paid	(199,959,213)	(196,834,850)	
Add: Net profit during the period	477,914,529	633,189,350	
	<u><u>3,903,572,930</u></u>	<u><u>3,625,617,615</u></u>	
15B. NON CONTROLLING INTERESTS:			
The IBN SINA API Industry Ltd.	200	200	
The IBN SINA Natural Medicine Ltd.	3,000	3,000	
The IBN SINA Polymer Industry Ltd. (Paid by IBN SINA Trust)	105,000,000	70,000,000	
Add: Share of Profit/(Loss)	259,984	943,396	
	<u><u>105,263,184</u></u>	<u><u>70,946,596</u></u>	

	Amount in Taka	
	31 December 2025	30 June 2025
16. LONG TERM FINANCE :		
i) From Al-Arafah Islami Bank PLC. Secured (Under Hire Purchase Shirkatul Melk-HPSM)	505,481,423	565,545,640
ii) From Pubali Bank PLC (Long Term -H.P.S.M) Pharma	320,230,135	307,123,287
Current maturity transferred to current liability		
iii) From Al-Arafah Islami Bank PLC Secured (Under Hire Purchase Shi Note -21	(59,722,928)	(119,445,855)
LONG TERM FINANCE - net off current maturity	765,988,631	753,223,072

i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial Position @ 12.50% of profit.

ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import capital machinery and motor vehicle under Hire Purchase Shirkatul Melk.

iii) HPSM is repayable in 84 monthly equal installment.

iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.

v) Information regarding loan fall due after five years.

Loan fall due from 2 to 5 years

336,987,615

377,030,427

Loan fall due from 6 to more years

429,001,015

376,192,645

765,988,631

753,223,072

16.A CONSOLIDATED LONG TERM FINANCE :

The IBN SINA Pharmaceutical Industry PLC	765,988,631	753,223,072
The IBN SINA API Industry Ltd.	218,789,352	221,482,304
	984,777,983	974,705,376

17. EMPLOYEE BENEFIT OBLIGATIONS:

Opening Balance	990,546	1,185,180
Provision during the period	74,300,000	97,491,986
Less: Paid during the period	(73,661,460)	(97,686,620)
	1,629,086	990,546

17. A CONSOLIDATED EMPLOYEE BENEFIT OBLIGATIONS:

Opening Balance	990,546	1,185,180
Provision during the period	96,167,189	137,250,512
Less: Paid during the period	(95,528,649)	(137,445,146)
	1,629,086	990,546

17. B LEASE LIABILITIES:

Opening Balance	23,798,698	50,336,979
Finance charge	946,143	3,692,459
Paid during the period	(14,923,915)	(30,230,740)
Closing balance	9,820,926	23,798,698
Less : Transferred to current maturity	(9,820,926)	(23,798,698)

i) The company has lease against its head office and its training center located at Mohammadpur, Dhaka.

ii) Lease period is upto 31.10.2026

iii) Monthly rental payment is Tk.1,851,270

iv) Advance amount paid Tk. 11,661,000

v) Monthly advance adjustment Tk. 50,000

Amount in Taka	
31 December 2025	30 June 2025

18. DEFERRED TAX LIABILITY:

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax expense/(income) have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,366,630,147	1,861,008,772	505,621,375	20.00%	101,124,275
Gratuity	75,290,547	73,661,460	(1,629,087)	20.00%	(325,817)
Lease	10,849,519	10,151,733	697,786	20.00%	139,557
Unrealized gain on marketable securities	(23,226,568)		(23,226,568)	10.00%	(2,322,657)
As at 31 December 2025	2,429,543,645	1,944,821,965	481,463,507		98,615,358
Property, plant and equipment	2,431,653,536	1,943,389,552	488,263,984	20.00%	97,652,797
Gratuity	98,677,167	97,686,620	(990,547)	20.00%	(198,109)
Lease	9,274,013	12,994,333	(3,720,320)	20.00%	(744,064)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10.00%	(1,727,148)
Bad Debt provision	1,358,626	-	(1,358,626)	20.00%	(271,725)
As at 30 June 2025	2,523,691,863	2,054,070,505	464,923,013		94,711,750
DEFERRED TAX EXPENSES/(INCOME) :					
Closing balance of deferred tax liability					98,615,358
Opening balance of deferred tax liability					94,711,750
Total deferred tax expenses/(income)					3,903,608
Less: Deferred tax (income)/ expenses related to other comprehensive income					(595,509)
					3,308,099
					(3,803,551)

19 CONSOLIDATED DEFERRED TAX LIABILITY:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,612,839,018	2,099,214,999	513,624,019		103,078,547
Gratuity	75,290,547	73,661,460	(1,629,087)	20% to 30%	(325,817)
Lease	10,498,840	10,151,733	347,107		43,120
Unrealized gain on marketable securities	(23,226,568)	-	(23,226,568)	10.00%	(2,322,657)
As at 31 December 2025	2,675,401,837	2,183,028,192	489,115,472		100,473,193
Property, plant and equipment	2,653,231,530	2,157,701,612	495,529,918	20% to 27.50%	99,530,336
Gratuity	148,665,292	147,674,745	(990,547)		(198,109)
Lease	8,813,099	12,994,333	(4,181,234)		(870,815)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10.00%	(1,727,148)
Bad Debt provision	1,358,626	-	(1,358,626)	20.00%	(271,725)
As at 30 June 2025	2,794,797,068	2,318,370,690	471,728,032		96,462,538

CONSOLIDATED DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	100,473,193	96,462,538
Opening balance of deferred tax liability	96,462,538	101,180,185
Total deferred tax expenses/(income)	4,010,655	(4,717,647)
Less: Deferred tax (income)/ expenses related to other comprehensive income	(595,509)	770,401
	3,415,146	(3,947,246)

20. SHORT TERM FINANCE :

A. From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities LC(MPI/TR/UPAS)	1,776,539,472	933,771,898
	1,776,539,472	933,771,898

i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of Statement of Financial Position @ 12.50% of profit and 0.25% commission per quarter to be paid.

ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite facilities LC/MPI/MPI TR/UPAS/ Baimuajjal agreement.

iii) Short term loan is repayable within twelve months.

iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.

	Amount in Taka	
	31 December 2025	30 June 2025
20.A CONSOLIDATED SHORT TERM FINANCE :		
A. From Al-Arafah Islami Bank Ltd. - Secured (Under Composite facilities LC(MPI/TR/UPAS))	1,776,539,472	933,771,898
B. The IBN SINA API Industry Ltd.	20,848,237	19,911,341
	<u>1,797,387,709</u>	<u>953,683,239</u>
21. CURRENT PORTION OF LONG TERM FINANCE:		
i) From Al-Arafah Islami Bank PLC-Secured (Under Hire Purchase Shirkatul Melk)	<u>59,746,323</u>	<u>119,445,855</u>
The amounts represent current maturity of long term finance obtained from Al-Arafah Islami Bank PLC and lease liability which are repayable within next 12 (Twelve) months from the date of Statement of Financial Position.		
22. TRADE AND OTHER PAYABLES:		
Payable to suppliers	527,462,373	354,248,263
Provisions	154,559,435	187,977,710
Accrued expenses	262,384,120	178,532,052
Security money received from employees and others	11,177,972	11,517,972
Workers' profit participation fund & welfare fund	30,061,938	42,953,850
	<u>975,645,837</u>	<u>775,229,847</u>
22.1 PROVISIONS:		
Opening balance	187,977,710	144,607,133
Provisions made during the period	154,559,435	187,977,710
Provisions used during the period	<u>(187,977,710)</u>	<u>(144,607,133)</u>
Closing balance	<u>154,559,435</u>	<u>187,977,710</u>
22.A CONSOLIDATED TRADE AND OTHER PAYABLES :		
Payable to suppliers	568,508,781	396,181,410
Provisions	154,559,435	187,977,710
Accrued expenses	262,260,925	203,253,644
Security money received from employees and others	11,177,972	11,517,972
Workers' profit participation fund & welfare fund	32,129,881	43,358,391
	<u>1,028,636,994</u>	<u>842,289,127</u>
Payable to suppliers increased during the period to meet business need.		
22.B UNCLAIMED DIVIDEND :		
Opening	42,104,508	39,140,597
Addition	199,959,213	196,834,850
Paid to share holders	<u>(169,345,162)</u>	<u>(186,963,608)</u>
Paid to Capital Market Stabilisation Fund	<u>(6,907,331)</u>	
	<u>72,718,559</u>	<u>42,104,508</u>
22.2 UNCLAIMED DIVIDEND :		
2021-22	10,214,969	12,953,290
2022-23	14,205,187	15,606,678
2023-24	12,854,100	13,544,540
2024-25	35,444,302	
	<u>72,718,559</u>	<u>42,104,508</u>
23. PROVISION FOR CORPORATE TAX:		
Opening balance	458,584,929	255,866,409
Current tax provision	129,701,593	202,718,520
	<u>588,286,523</u>	<u>458,584,929</u>
23.A CONSOLIDATED INCOME TAX PAYABLES:		
Opening balance	495,245,930	284,580,559
Current tax expense	141,903,654	210,665,371
	<u>637,149,585</u>	<u>495,245,930</u>

	Amount in Taka	
	For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)
24. REVENUE:		
Local revenue	6,568,191,774	5,311,628,119
Export revenue	88,127,629	98,290,535
	6,656,319,403	5,409,918,654
24.A CONSOLIDATED REVENUE:		
The IBN SINA Pharmaceutical Industry PLC	6,656,319,403	5,409,918,654
The IBN SINA Natural Medicine Ltd	808,850,349	520,127,637
	7,465,169,752	5,930,046,291
24.B COST OF GOODS SOLD :		
Materials	3,251,068,111	2,675,262,571
Factory Overhead	643,015,437	478,077,285
Depreciation	67,307,505	70,406,748
	3,961,391,054	3,223,746,603
24.C CONSOLIDATED COST OF GOODS SOLD :		
Materials	3,602,706,143	2,901,518,093
Factory Overhead	740,716,398	558,697,069
Depreciation	70,487,738	73,813,668
	4,413,910,280	3,534,028,829
25. ADMINISTRATIVE EXPENSES :		
Salary, Wages & Allowances	63,820,044	63,567,515
Repairs & Maintenance	4,475,641	9,072,702
Travelling & Conveyance	4,378,621	2,627,748
AGM, Fees and Others	1,863,488	1,475,021
Depreciation	13,283,436	13,296,495
Other Expenses	27,072,649	32,081,411
	114,893,879	122,120,893
Less: Expenses for INM	(12,533,233)	(9,472,142)
	102,360,646	112,648,751
25.A CONSOLIDATED ADMINISTRATIVE EXPENSES :		
Salary, Wages & Allowances	70,574,917	67,676,922
Repairs & Maintenance	7,812,093	9,864,673
Travelling & Conveyance	4,378,621	2,627,748
AGM, Fees and Others	1,863,488	1,977,954
Research & Development	1,417,174	221,263
Depreciation	17,597,700	17,414,296
Other Expenses	31,730,193	34,332,163
	135,374,187	134,115,019

- i) Salary, wages & allowance increased due to increase in manpower, gratuity payment.
- ii) Repairs & Maintenance expense decreased due to decrease in maintenance of fixed assets to meet business needs.
- iii) Travelling & conveyance increased during the period due to increase travel.
- iv) Research & development expense increased during this period due to meet business needs.
- iv) Depreciation expense during the reporting period increased due to addition of fixed assets .

	Amount in Taka	
	For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)
26. SELLING & DISTRIBUTION EXPENSES :		
Salary, Wages & Allowances	1,034,334,780	868,657,372
Travelling & Conveyance	3,700,164	4,360,057
Market Survey & Research and Product development	4,473,744	3,243,031
Field personnel expenses	280,953,259	180,972,115
Sample, Literature & Promotional Expenses	191,880,137	113,936,626
Delivery Expenses	256,861,570	152,426,107
Depreciation	19,559,692	21,031,487
Other Expenses	168,439,518	215,456,981
	1,960,202,865	1,560,083,776
Less: Expenses for INM	(32,354,014)	(20,805,105)
	1,927,848,851	1,539,278,671

26.A CONSOLIDATED SELLING & DISTRIBUTION EXPENSES :

Salary, Wages & Allowances	1,221,726,440	1,024,615,340
Travelling & Conveyance	6,395,744	5,938,539
Market Survey & Research and Product development	4,473,744	3,243,031
Field personnel expenses	326,019,127	219,319,478
Sample, Literature & Promotional Expenses	213,652,536	147,351,034
Delivery Expenses	256,861,570	152,426,106
Depreciation	19,788,912	21,243,927
Other Expenses	179,146,257	222,654,144
	2,228,064,330	1,796,791,600

- i) Travelling & conveyance increased during the period due to increase travel.
- ii) Field personal and delivery expense during the reporting period increased due to increase in fuel and gas cost and vehicles rent cost.
- iii) Depreciation expense during the reporting period decreased due to disposal of fixed assets .

27. WORKERS' P.P FUND & WELFARE FUND :	30,061,938	23,993,196
---	-------------------	-------------------

27.A CONSOLIDATED WORKERS' P.P FUND & WELFARE FUND :

The IBN SINA Pharmaceutical Industry PLC	30,061,938	23,993,196
The IBN SINA Natural Medicine Ltd.	2,067,943	1,297,611
	32,129,881	25,290,807

28. INCOME TAX EXPENSES:

Current Tax	129,701,593	106,324,177
Deferred Tax income/(expense)	3,308,099	6,612,236
	133,009,692	112,936,413

Reconciliation of Effective Tax Rate

Types of income	Income	Effective Tax Rate	Tax
Capital Gain		20.00%	
Business Income	601,238,759	20.00%	120,247,752
	601,238,759	20.00%	120,247,752
Non Deductible Expenses		1.57%	9,453,842
Deferred Tax (income)/expense		0.55%	3,308,099
		22.12%	133,009,692

	Amount in Taka	
	For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)
28.A CONSOLIDATED INCOME TAX EXPENSES:		
Current Tax	141,903,654	110,330,579
Deferred Tax income/(expense)	3,415,147	6,597,297
	145,318,801	116,927,876

Reconciliation of Effective Tax Rate

Types of income	Income	Effective Tax Rate	Tax
Capital Gain		20.00%	
Business Income	622,549,918	20% to 27.50%	128,528,911
	622,549,918	20.65%	128,528,911
Non Deductible Expenses		1.52%	9,453,842
Deferred Tax (income)/expense		0.53%	3,308,099
		22.70%	141,290,851

29. CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES :

Closing value of marketable securities	(23,226,568)	(12,623,929)
Opening value of marketable securities	(17,271,479)	(9,567,467)
	(5,955,089)	(3,056,462)

30. EARNINGS PER SHARE (EPS) :

Basic earnings per share has been calculated as follows :		
Earnings attributable to the Ordinary Shareholders (Net profit after tax)	468,229,066	366,927,499
Divided by number of Ordinary Shares outstanding during the year/period	31,243,627	31,243,627
EARNINGS PER SHARE (EPS)	14.99	11.74

30.A CONSOLIDATED EARNINGS PER SHARE (EPS) :

Basic earnings per share has been calculated as follows :		
Earnings attributable to the Ordinary Shareholders (Net profit after tax)	477,231,117	295,867,185
Divided by number of Ordinary Shares outstanding during the year/period	31,243,627	31,243,627
CONSOLIDATED EARNINGS PER SHARE (EPS) :	15.27	9.47

31. NET ASSETS VALUE PER SHARE (NAV)

Equity attributable to the owners of the company	4,195,293,329	3,932,383,056
Divided by weighed average number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
Net Assets Value Per Share (NAV)	134.28	125.86

Net Assets Value Per Share (NAV) increased during the period due to increase in sales, maintaining stable expenses growth and increase in retained earning.

31.A CONSOLIDATED NET ASSETS VALUE PER SHARE (NAV):

Net Assets Value	4,199,497,399	3,926,901,664
Divided by weighed average number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
Consolidated Net Assets Value Per Share (NAV):	134.41	125.69

	Amount in Taka	
	For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)
32. NET OPERATING CASH FLOW PER SHARE (NOCFPS):		
Net cash provided by operating activities	749,845,390	507,212,831
Divided by weighed average number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
	<u>24.00</u>	<u>16.23</u>
32.A CONSOLIDATED NET OPERATING CASH FLOWS PER SHARE (NOCFPS):		
Net cash provided by operating activities	767,873,543	538,814,680
Divided by weighed average number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
	<u>24.58</u>	<u>17.25</u>
33. RECONCILIATION OF NET PROFIT WITH CASH FLOWS FROM OPERATING ACTIVITIES:		
Profit Before Tax (PBT)	601,238,759	479,863,911
Adjustment		
Depreciation	100,150,632	98,184,730
Deferred Tax	3,903,608	6,917,882
Unrealized foreign exchange loss	(3,423,332)	46,902
Share of associate profit/Loss	1,270,038	1,247,355
Gain on sale of Motor Vehicles		
Dividend received		1,869,684
Interest Income	(1,656,524)	
Change In operating assets		
Increase in inventory	(63,118,694)	(27,221,822)
Increase in accounts receivables	(28,144,840)	(5,820,181)
Decrease in advances, deposits and prepayments	1,582,663	6,942,226
Increase/(decrease) in trade and other payable	262,360,562	58,231,441
Increase/(decrease) in retirement benefit obligation	638,540	511,076
Finance charge	(50,506,436)	(36,620,120)
Tax paid during the period	(74,449,586)	(76,940,255)
	<u>749,845,390</u>	<u>507,212,831</u>
34. Finance Charge:		
Finance charge for long term finance	50,506,436	36,620,120
Finance charge for lease	946,143	2,133,503
	<u>51,452,579</u>	<u>38,753,623</u>
34.A Consolidated Finance Charge:		
Finance charge for long term finance	50,506,436	36,620,120
Finance charge for lease	946,143	2,133,503
	<u>51,452,579</u>	<u>38,753,623</u>



35. RELATED PARTY DISCLOSURE:

Name of party	Relations hip	Nature of transaction	Transaction		Dec' 2025	June 2025
			Dr.	Cr.	Receivable/(Payable)	
The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital		40,000,000	709,999,800	669,999,800
The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share Capital			238,169,670	238,169,670
		Administrative Expenses	12,533,233			
		Distribution Expense	32,354,014			
The IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Acquisition of share Capital		65,000,000	195,000,000	130,000,000

35.01. NON-CONTROLLING INTEREST

The IBN SINA API Industry Ltd.
The IBN SINA Natural Medicine Ltd.
The IBN SINA Polymer Industry Ltd.

Profit Amount	NCI (%)	Net Amount
(18,554,363)	0.000050	(9)
29,210,175	0.001260	368
(1,953,631)	35.000000	(683,771)
8,702,181		(683,412)


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director


Chairman